2[2]Creaney J,Yeoman D,Naumoff LK,et al.Soluble me-sothelin in effusions:a useful tool for the diagnosis of malignant mesothelioma[J].Thorax,2007,62(7):569-576.
5[5]Ma GY,Bartlett DL,Reed E,et al.Continuous hy-perthemic peritoneal perfusion with cisplatin for the treatment of peritoneal mesotheliomaEJ].Cancer J Sci Am,1997,3(3):174-179.
6[6]Alexander HR,Hanna N,Pingpank JF.Clinical re-suits of cytoreduction and HIPEC for malignant perito-neal mesothelioma[J].Cancer Treat Res,2007,134:343-355.
7[7]Yan TD,Sim J,Sugarbaker PH.So13p cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothe-lioma-analysis of 100 consecutive patients from a pro-spective database[J].ANZ J Surg,2007,77(Suppl 1):A88-89.
8[8]Yan TD,Welch L,Black D,et al.A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma[J].Ann Oncol,2007,18(5):827-834.
9[9]Cerruto CA,Brun EA,Chang D,et al.Prognostic sig-nificance of histomorphologic parameters in diffuse ma-lignant peritoneal esothelioma[J].Arch Pathol Lab Med,2006,130(11):1 654-1 661.
10[10]Yan TD,Brun EA,Cerruto CA,et al.Prognostic in-dicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for dif-fuse malignant peritoneal mesothelioma[J].Ann Surg Oncol,2007,14(1):41-49.
